Evidence map›Paper›PMID 38617116›Full record

ArticleOpen research Europe2023

Rapid diagnostic testing for onchocerciasis in Maridi (South Sudan) before and after improving elimination strategies: a repeated cross-sectional survey.

Amber Hadermann, Stephen Raimon Jada, Luís-Jorge Amaral, Robert Colebunders, Yak Yak Bol, Joseph N Siewe Fodjo

Abstract read
In one paragraph

Article in Open research Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amber HadermannGlobal Health Institute, University of Antwerp, Antwerp, Flanders, 2610, Belgium.ORCID https://orcid.org/0000-0003-1207-5811
Stephen Raimon JadaAmref Health Africa South Sudan, Juba, South Sudan.
Luís-Jorge AmaralGlobal Health Institute, University of Antwerp, Antwerp, Flanders, 2610, Belgium.ORCID https://orcid.org/0000-0001-8155-9014
Robert ColebundersGlobal Health Institute, University of Antwerp, Antwerp, Flanders, 2610, Belgium.ORCID https://orcid.org/0000-0002-1919-1340
Yak Yak BolNeglected Tropical Diseases Programme, Ministry of Health, Juba, South Sudan.
Joseph N Siewe FodjoGlobal Health Institute, University of Antwerp, Antwerp, Flanders, 2610, Belgium.ORCID https://orcid.org/0000-0003-3544-1239

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Maridi County is an onchocerciasis-endemic area in South Sudan. Annual community-directed treatment with ivermectin (CDTi) was instituted in Maridi since the early 2000s, but with low coverage. In 2021, the CDTi programme was strengthened to a six-monthly programme. Additionally, the community-based vector control strategy "Slash and Clear" has been implemented since 2019 at the Maridi Dam, the only blackfly breeding site in the area. This study assessed the effect of these reinforced onchocerciasis elimination interventions on the Methods: Baseline and follow-up serosurveys were conducted in Maridi in 2019 (prior to strengthening onchocerciasis elimination efforts) and 2023, respectively. During both surveys, children aged three to nine years were recruited from five study sites situated at different distances from the Maridi Dam. Ov16 antibodies were detected via rapid diagnostic tests (RDTs) using whole blood obtained by finger-pricking the participants. Baseline and follow-up Ov16 prevalence rates were calculated and compared. Results: In 2019, the Ov16 seroprevalence among children aged three to nine years was 24.5% compared to 30.6% in 2023 (p=0.22). Both surveys found a particularly high Ov16 seroprevalence in the study site closest to the Maridi Dam (35.0% in 2019 and 44.0% in 2023, p=0.52). The Ov16 seroprevalence had a non-significant decreasing trend in the three-year-old children, from 12.5% (3/24) in 2019 to 8.8% (3/34) in 2023 (p=0.65). Conclusion: The persistent Ov16 RDT seropositivity among three-year-old children in 2023 indicates ongoing

Indexed as

antibodieschildrenivermectinOnchocerca volvulusOnchocerciasisseroprevalencetestingtransmissionvector control

Identifiers

PMID38617116
PMCPMC11016167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.